# Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent

> **NCT02431650** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 11 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** OZ439
- **DRUG:** Primaquine

## Key facts

- **NCT ID:** NCT02431650
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-05-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431650, "Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02431650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*